Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novo Nordisk A/S (NYSE:NVO)

44.88
Delayed Data
As of Sep 23
 -0.69 / -1.51%
Today’s Change
44.04
Today|||52-Week Range
59.00
-22.73%
Year-to-Date
Novo Nordisk (NVO) Presents Data on Obesity Drug Saxenda
Sep 15 / Zacks.com - Paid Partner Content
Why Novo Nordisk Stock Dropped 18.9% in August
Sep 12 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close45.57
Today’s open44.58
Day’s range44.52 - 45.12
Volume3,873,940
Average volume (3 months)2,228,034
Market cap$88.0B
Dividend yield2.02%
Data as of 4:02pm ET, 09/23/2016

Growth & Valuation

Earnings growth (last year)+12.05%
Earnings growth (this year)--
Earnings growth (next 5 years)+10.70%
Revenue growth (last year)+1.43%
P/E ratio3.2
Price/Sales9.38
Price/Book16.73

Competitors

 Today’s
change
Today’s
% change
LLYEli Lilly and Co-0.13-0.16%
AZNAstraZeneca-0.31-0.90%
CELGCelgene-1.14-1.03%
BMYBristol-Myers Squibb+0.06+0.11%
Data as of 4:03pm ET, 09/23/2016

Financials

Next reporting dateOctober 28, 2016
EPS forecast (this quarter)$0.57
Annual revenue (last year)$16.0B
Annual profit (last year)$5.2B
Net profit margin32.30%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
President &
Chief Executive Officer
Lars Rebien Sørensen
Chief Financial Officer &
Executive Vice President
Jesper Brandgaard
Corporate headquarters
Bagsværd, Capital Region

Forecasts

Search for Jobs